Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 8:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Biopsy Clear all
Completed No phase listed Observational

A Retrospective Multicenter Review to Evaluate the Performance of the Ion Endoluminal System in Sampling Pulmonary Lesions

NCT05160571
View directory record Official record
Conditions
Lung Cancer, Pulmonary Nodule
Interventions
Ion Endoluminal System
Device
Lead sponsor
Intuitive Surgical
Industry
Eligibility
18 Years and older
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Winchester, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Sep 28, 2026, 8:08 AM EDT
Recruiting Phase 2 Interventional

Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial

NCT07436793
View directory record Official record
Conditions
Endometrial Endometrioid Adenocarcinoma, Endometrial Hyperplasia
Interventions
Biopsy Procedure, Curettage Procedure, Hysterectomy, Megestrol Acetate, Progesterone Only Hormone Replacement Therapy
Procedure · Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
4
States / cities
Iowa City, Iowa • Albuquerque, New Mexico • Salt Lake City, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 28, 2026, 8:08 AM EDT
Terminated Phase 2 Interventional Results available

A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma

NCT02050321
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Acitretin, Vemurafenib
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 25, 2018 · Synced Sep 28, 2026, 8:08 AM EDT
Recruiting Early Phase 1 Interventional

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

NCT04005690
View directory record Official record
Conditions
Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
Interventions
Cobimetinib, Olaparib, Onvansertib, Azenosertib, Saruparib, Tremelimumab
Drug · Biological
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 28, 2026, 8:08 AM EDT
Not yet recruiting No phase listed Observational

Spatial Computing With the Apple Vision Pro in Image-guided Procedures

NCT07819513
View directory record Official record
Conditions
Apple Vision Pro, Image Guided Procedure, Spatial Computing
Interventions
CT guided biopsy
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 28, 2026, 8:08 AM EDT
Completed Not applicable Interventional

Intraluminal Endosonography for Examination of the Structural Changes of the Stomach in Gastroparetic Patients

NCT01916460
View directory record Official record
Conditions
Idiopathic Gastroparesis, Diabetic Gastroparesis
Interventions
Endoscopic Ultrasound Fine Needle Aspiration (EUS-FNA)
Procedure
Lead sponsor
Texas Tech University Health Sciences Center, El Paso
Other
Eligibility
18 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Sep 28, 2026, 8:08 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Feasibility Study for Fibroblast Autologous Skin Grafts

NCT01964859
View directory record Official record
Conditions
Wounds and Injuries
Interventions
autologous skin fibroblasts, Filler Product
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 28, 2026, 8:08 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

NCT02356159
View directory record Official record
Conditions
Myelodysplastic Syndromes, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Acute Leukemia, Multiple Myeloma
Interventions
Rituximab, Conditioning chemotherapy, TMS, FLAG, EPOCH-F, Hematopoietic stem cell transplant, Palifermin, Acetaminophen, Diphenhydramine, Prednisone, Epinephrine, IV Saline, ECG, ECHO, MUGA, DEXA, CT chest, PET, MRI, BM aspirate, BM biopsy, Lumbar puncture
Biological · Drug · Procedure + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
2
States / cities
Bethesda, Maryland • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 28, 2026, 8:08 AM EDT
Recruiting Phase 2 Interventional

NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer

NCT05837455
View directory record Official record
Conditions
Breast Cancer, Cancer of the Breast
Interventions
VENTANA MIB-1 Ki67 assay, Oncotype DX® Recurrence Score, PAM50-based Prosigna breast cancer gene signature assay, Anastrozole, Combination anthracycline and/or taxane based treatment
Device · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 28, 2026, 8:08 AM EDT
Active, not recruiting No phase listed Observational

Biological Sample Repository for Gastrointestinal Disorders

NCT05874726
View directory record Official record
Conditions
Obesity, Obesity, Morbid, Obesity, Primary, Gastro-Intestinal Disorder, Overweight and Obesity, Overweight, Overweight or Obesity, Diabetes Type 2, Diabetes Mellitus, Diabetes Mellitus, Type 2, Hypertension, Hyperlipidemias, Sleep Apnea, GERD, Gastroesophageal Reflux, Musculoskeletal Pain Disorder, Cancer
Interventions
Blood Collection, Urine Collection, Tissue Sample Collection
Diagnostic Test
Lead sponsor
Pichamol Jirapinyo, MD, MPH
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Sep 28, 2026, 8:08 AM EDT
Completed Phase 1Phase 2 Interventional

Utility of Endobronchial Ultrasound Guided Needle Biopsy in Early Stage Non- Small Cell Lung Cancer (NSCLC)

NCT00832715
View directory record Official record
Conditions
Lung Cancer
Interventions
EBUS-TBNA
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Sep 28, 2026, 8:08 AM EDT
Recruiting No phase listed Observational

Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining

NCT00242723
View directory record Official record
Conditions
Thoracic Cancers, Malignant Pleural Mesotheliomas NOS, Lung Cancer NOS, Esophageal Cancers NOS, Cancers of Non Thoracic Origin With Metastases to the Lungs or Pleura, Thoracic Malignancies
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 120 Years
Enrollment
1,559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 28, 2026, 8:08 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2

NCT05833217
View directory record Official record
Conditions
Long COVID, Insulin Resistance, Insulin Sensitivity
Interventions
Adipose Tissue Biopsy, Steady State Plasma Glucose (SSPG) Test
Procedure · Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Sep 28, 2026, 8:08 AM EDT
Withdrawn Phase 2 Interventional

Rituximab for GVHD

NCT00578591
View directory record Official record
Conditions
Graft vs Host Disease, Alogenic Hematopoietic Transplant
Interventions
Rituximab
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2012 · Synced Sep 28, 2026, 8:08 AM EDT
Recruiting Phase 2 Interventional

Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)

NCT06160791
View directory record Official record
Conditions
Hemophagocytic Lymphohistiocytoses
Interventions
Ruxolitinib, Etoposide, Dexamethasone, Non-interventional Imaging, Research Biopsy, Biospecimen Collection
Drug · Procedure
Lead sponsor
Jerry Lee, MD, MSc, MPhil
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
4
States / cities
Irvine, California • Sacramento, California • San Diego, California + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 28, 2026, 8:08 AM EDT
Completed Not applicable Interventional Results available

Comparing a 25G EUS Fine Needle Aspiration (FNA) Device With a 20G EUS

NCT02167074
View directory record Official record
Conditions
Pancreatic Masses, Lymph Nodes
Interventions
25G FNA needle, 20G ProCore FNB needle
Device
Lead sponsor
Foundation for Liver Research
Other
Eligibility
18 Years to 100 Years
Enrollment
615 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
Irvine, California • New Haven, Connecticut • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 22, 2021 · Synced Sep 28, 2026, 8:08 AM EDT
Completed No phase listed Observational

De Novo Lipogenesis in Severity of NAFLD

NCT03683589
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Bariatric Surgery Candidate, Obesity, Morbid
Interventions
Not listed
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
22 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Sep 28, 2026, 8:08 AM EDT
Completed Phase 4 Interventional Results available

deLIVER: Direct Acting Antiviral Effects on the Liver

NCT02938013
View directory record Official record
Conditions
HCV Coinfection, Liver Disease, HIV
Interventions
Sofosbuvir/Velpatasvir/Voxilaprevir [SOF/VEL/VOX], Sofosbuvir/Velpatasvir (SOF/VEL)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Sep 28, 2026, 8:08 AM EDT
Recruiting Phase 1 Interventional

A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

NCT06799026
View directory record Official record
Conditions
Multiple Myeloma, Relapse Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Elranatamab, GM-CSF, DC/MM Fusion Vaccine
Drug · Biological
Lead sponsor
David Avigan
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 28, 2026, 8:08 AM EDT
Withdrawn Phase 2 Interventional

Ciprofloxacin Compared to Placebo in Diagnosing Prostate Cancer in Patients Undergoing Prostate Biopsy

NCT02252978
View directory record Official record
Conditions
Prostate Cancer
Interventions
ciprofloxacin, placebo, quality-of-life assessment, laboratory biomarker analysis
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Salisbury, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Sep 28, 2026, 8:08 AM EDT
Completed Phase 1 Interventional

D2C7 for Adult Patients With Recurrent Malignant Glioma

NCT02303678
View directory record Official record
Conditions
Malignant Glioma, Brain Tumor, Recurrent
Interventions
D2C7-IT
Drug
Lead sponsor
Darell Bigner
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 28, 2026, 8:08 AM EDT
Completed No phase listed Observational

Study of Eye Tissue for Sarcoidosis

NCT00001278
View directory record Official record
Conditions
Sarcoidosis
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 28, 2026, 8:08 AM EDT
Completed Phase 2 Interventional Results available

Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis

NCT01710046
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
(CP-6890,550) Tofacitinib, Placebo, (CP-690,550) Tofacitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
5
States / cities
Los Angeles, California • Tampa, Florida • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2015 · Synced Sep 28, 2026, 8:08 AM EDT
Completed Phase 4 Interventional Results available

Immunologic Response to Secukinumab in Plaque Psoriasis

NCT02592018
View directory record Official record
Conditions
Psoriasis
Interventions
Secukinumab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Sep 28, 2026, 8:08 AM EDT